# Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

> **NCT05164250** · — · APPROVED_FOR_MARKETING · sponsor: **Regeneron Pharmaceuticals**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** REGN5458

## Key facts

- **NCT ID:** NCT05164250
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164250, "Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05164250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*